News & Updates
Filter by Specialty:
Mediterranean diet counselling may help counter overweight/obesity in the offspring
A personalized nutritional counselling targeting adherence to the Mediterranean diet (MD) during pregnancy may be an effective strategy against childhood overweight/obesity, findings from the PREMEDI study have shown.
Mediterranean diet counselling may help counter overweight/obesity in the offspring
23 Jun 2023
HK data: No correlation between ADHD medication prescriptions and poisoning events
No significant correlation is observed between prescriptions of medications for attention deficit/hyperactivity disorder (ADHD) and poisoning cases involving ADHD medications in Hong Kong, a descriptive analysis has shown.
HK data: No correlation between ADHD medication prescriptions and poisoning events
23 Jun 2023
Nivolumab-AVD superior to brentuximab vedotin-AVD for advanced stage Hodgkin lymphoma
Treatment with nivolumab (N) plus doxorubicin, vinblastine, and dacarbazine (AVD) leads to improved progression-free survival (PFS) relative to brentuximab vedotin (BV) plus AVD in patients with advanced stage classic Hodgkin lymphoma (HL), according to the results of the SWOG S1826 study, which was presented at the recent ASCO 2023.
Nivolumab-AVD superior to brentuximab vedotin-AVD for advanced stage Hodgkin lymphoma
22 Jun 2023
GBDT model predicts IVIG-resistant Kawasaki disease
The gradient boosting decision tree (GBDT) model appears more reliable than previous models in predicting intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD), reports a study.
GBDT model predicts IVIG-resistant Kawasaki disease
22 Jun 2023
Erdafitinib prevails in bladder cancer with select FGFRalt
The oral selective pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib demonstrated a survival advantage over chemotherapy, extending multiple efficacy endpoints in individuals with advanced or metastatic urothelial carcinoma (mUC) with FGFR alterations (FGFRalt) after previous anti-PD-(L)1 treatment, findings from the confirmatory phase III THOR trial have shown.
Erdafitinib prevails in bladder cancer with select FGFRalt
22 Jun 2023
SGLT2 inhibitors score big, this time in gout
Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.